DNA疫苗诱导肿瘤特异性新表位CD8+ T细胞应答
本研究在小鼠中比较了同源自身抗原与异源病毒载体编码的肿瘤新表位Db/Sp244-252/R251H诱导CD8+ T细胞的能力。单次注射表达载体即可有效激活特异性效应CD8+ T细胞,且不依赖CD4+ T细胞辅助。异源HBV核心颗粒载体诱导的CD8+ T细胞频率与杀伤表型与同源载体相当,但未诱导自身抗原特异性IgG。
要点
- 单次DNA免疫即可诱导新表位特异性效应CD8+ T细胞。
- 新表位CD8+ T细胞 priming 不依赖CD4+ T细胞辅助。
- 异源HBV核心载体可选择性诱导CD8+ T细胞而避免自身抗体应答。
核心结论
- DNA疫苗编码的肿瘤新表位可在小鼠中有效诱导特异性效应CD8+ T细胞。
- 异源HBV核心表达平台可选择性诱导新表位特异性CD8+ T细胞,避免自身抗原特异性抗体应答。
研究设计与样本
- 在C57Bl/6J小鼠中通过DNA免疫比较同源Endophilin-B2载体与嵌合HBV核心载体编码的Db/Sp244-252/R251H新表位诱导CD8+ T细胞的效果。
- 在MHC-II缺陷Aα-/-小鼠中评估CD4+ T细胞辅助对新表位CD8+ T细胞 priming 的影响。
主要发现
- 单次注射EndoB2-Sp表达载体有效 priming 二聚体/五聚体+、IFN-γ+和细胞溶解性Db/Sp244-252/R251H特异性效应CD8+ T细胞。
- 在MHC-II缺陷Aα-/-小鼠中,Db/Sp244-252/R251H特异性CD8+ T细胞 priming 独立于CD4+ T细胞辅助。
- 与同源EndoB2-Sp疫苗相比,嵌合HBV核心抗原选择性表达新表位诱导频率相当的Db/Sp244-252/R251H特异性CD8+ T细胞,且具有相同的细胞溶解效应表型。
- 同源EndoB2载体诱导EndoB2特异性IgG抗体应答,而嵌合HBV核心颗粒展示的九肽新表位未诱导该应答。
临床怎么用
- 异源HBV核心表达平台可作为DNA疫苗选择性诱导肿瘤新表位特异性效应CD8+ T细胞的候选策略。
- 设计异源/自身或异源/病毒癌症疫苗时,需考虑载体对CD8+ T细胞 priming 和激活新表位特异性CD8+ T细胞的影响。
局限性
- 研究仅在小鼠模型中进行,尚未在人类中验证。
- 未报告长期免疫记忆或抗肿瘤保护效果的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatic mutations in tumors often generate neoproteins that contain MHC-I-binding neoepitopes. Little is known if and how efficient tumor-specific neoantigens activate CD8+ T cells. Here, we asked whether a de novo generated neoepitope, encoded either within an otherwise conserved and ubiquitously expressed self-antigen or in a chimeric HBV core antigen expression platform, providing heterologous helper functions, induces CD8+ T cells in C57Bl/6J mice by DNA immunization. For it, we chose an established Db/Sp244-252/R251H neoepitope generated in the murine Endophilin-B2/SH3GLB2 (EndoB2-Sp) protein by a single amino acid exchange. We showed that a single injection of EndoB2-Sp expression vectors efficiently primed dimer/pentamer+, IFN-γ+ and cytolytic Db/Sp244-252/R251H-specific effector CD8+ T cells in C57Bl/6J mice. Priming of Db/Sp244-252/R251H-specific CD8+ T cells proceeded independent from CD4+ T-cell help in MHC-II-deficient Aα-/- mice. As compared to the homologous EndoB2-Sp vaccine, the selective expression of the Db/Sp244-252/R251H neoepitope in chimeric particle-forming and assembly-deficient HBV core antigens induced comparable frequencies Db/Sp244-252/R251H-specific CD8+ T cells with the same cytolytic effector phenotype. The homologous EndoB2 carrier, but not the nine-residue neoepitope presented on chimeric HBV core particles, induced EndoB2-specific IgG antibody responses. The HBV core expression platform is thus an attractive option to selectively induce neoepitope-specific effector CD8+ T cells by DNA vaccination. These novel findings have practical implications for the design of heterologous/self and heterologous/viral cancer vaccines that prime and/or activate neoepitope-specific CD8+ T cells.
引用
- Stifter K, Dekhtiarenko I, Krieger J, et al. A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8+ T-cell responses by DNA vaccination. Vaccine. 2020. PMID: 32278524. doi:10.1016/j.vaccine.2020.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。